Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Sequent Scientific's net profit margin of 2.1% in FY2025 reflects weak profitability, with operating margin at 6.0% and gross margin at 47.7%.
In FY 2025, Sequent Scientific posted a gross margin of 47.7%, an operating margin of 6.0%, a net margin of 2.1%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Sequent Scientific's revenue grew 12.4% to 15.51B and net profit grew 208.9% to 322.59M YoY in FY2025, indicating healthy business momentum.
In FY 2025, Sequent Scientific's revenue grew by 12.4% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Sequent Scientific's ROE of 4.2% in FY2025 indicates weak shareholder returns.
In FY 2025, Sequent Scientific reported an ROE of 4.2%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Sequent Scientific's FCF/NI ratio of 1.37x in FY2025 indicates high-quality, cash-backed earnings.
In FY 2025, Sequent Scientific's free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Sequent Scientific's OCF/NI ratio of 2.58x in FY2025 indicates strong cash collection and working capital efficiency.
In FY 2025, Sequent Scientific's operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Sequent Scientific's current ratio of 1.73x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Sequent Scientific reported a current ratio of 1.73. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Sequent Scientific's interest coverage ratio of 1.5x in FY2025 indicates acceptable but limited debt servicing headroom.
In FY 2025, Sequent Scientific reported an interest coverage ratio of 1.5x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Sequent Scientific's debt-to-equity ratio of 0.62x in FY2025 reflects a balanced capital structure with moderate leverage.
In FY 2025, Sequent Scientific reported a debt-to-equity ratio of 0.62. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Sequent Scientific's debt decreased 1.3% YoY in FY2025 — positive deleveraging improves financial flexibility.
In FY 2025, Sequent Scientific's total debt decreased by 1.3% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Sequent Scientific's diluted shares increased 2.6% YoY in FY2025 — share dilution.
Over 2 years (FY2024–FY2025), diluted shares increased 2.6% from 249.88M to 256.27M, indicating cumulative dilution.
In FY 2025, Sequent Scientific's diluted shares increased by 2.6% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025